A new drug-device combination, which is a non-surgical, tissue-preserving therapeutic procedure to more effectively remove HPV infection and treat precursors of cervical cancer, has been accepted for use in a phase II clinical trial by the FDA. Cevira, which is being developed by Photocure (Oslo, Norway), with the help of Sagentia (Cambridge, UK), is slated to be evaluated in clinical trials with sites throughout the U.S. and Europe during the spring of 2011, both companies report. (Medical Device Daily)